Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenrispodun - Intra-Cellular Therapies

Next Previous
Search
Drug Profile

Lenrispodun - Intra-Cellular Therapies

Alternative Names: IC 200214-12; IC-200214; IC200214 phosphate; ITI 214; ITI-002; ITI-12-Cyclo-(S,R) phosphate; ITI-214 phosphate; ITI12-phosphate; ITI200214-phosphate; Lenrispodun phosphate

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Aniline compounds; Antihypertensives; Antiparkinsonians; Cyclopentanes; Fluorinated hydrocarbons; Heart failure therapies; Imidazoles; Ketones; Nootropics; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Adenosine A2B receptor modulators; Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Phase I/II Heart failure
  • Preclinical Colorectal cancer; Hypertension
  • No development reported Cognition disorders

Most Recent Events

  • 02 Apr 2025 Intra-Cellular Therapies has been acquired by Johnson & Johnson
  • 13 Mar 2023 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in USA (PO)
  • 01 Mar 2023 Intra-Cellular Therapies plans a phase II trial for Parkinson’s disease in March 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top